Terms: = Pancreatic cancer AND TGFBR2, AAT3, 7048, ENSG00000163513, P37173, TGFbeta-RII, RIIC, TAAD2, FAA3, TGFR-2, MFS2, HNPCC6 AND Treatment
11 results:
1. Dysregulation of the circ_0087502/miR-1179/tgfbr2 pathway supports gemcitabine resistance in pancreatic cancer.
Chen M; Liu X; Lu J; Teng H; Yu C; Liu Y; Zheng Y
Cancer Biol Ther; 2023 Dec; 24(1):2258566. PubMed ID: 37844011
[TBL] [Abstract] [Full Text] [Related]
2. ST6GALNAC4 promotes hepatocellular carcinogenesis by inducing abnormal glycosylation.
Man D; Jiang Y; Zhang D; Wu J; Ding B; Liu H; Xu G; Lu J; Ru J; Tong R; Zheng S; Chen D; Wu J
J Transl Med; 2023 Jun; 21(1):420. PubMed ID: 37381011
[TBL] [Abstract] [Full Text] [Related]
3. USP33 promotes pancreatic cancer malignant phenotype through the regulation of tgfbr2/TGFβ signaling pathway.
Liu X; Xu J; Shen B; Xu J; Jiang J
Cell Death Dis; 2023 Jun; 14(6):362. PubMed ID: 37322017
[TBL] [Abstract] [Full Text] [Related]
4. Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical study.
de Castro Silva I; Bianchi A; Deshpande NU; Sharma P; Mehra S; Garrido VT; Saigh SJ; England J; Hosein PJ; Kwon D; Merchant NB; Datta J
Elife; 2022 Sep; 11():. PubMed ID: 36107485
[TBL] [Abstract] [Full Text] [Related]
5. Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in pancreatic cancer.
Dosch AR; Singh S; Dai X; Mehra S; Silva IC; Bianchi A; Srinivasan S; Gao Z; Ban Y; Chen X; Banerjee S; Nagathihalli NS; Datta J; Merchant NB
Mol Cancer Ther; 2021 Nov; 20(11):2280-2290. PubMed ID: 34518296
[TBL] [Abstract] [Full Text] [Related]
6. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in pancreatic Ductal Adenocarcinoma.
Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
[TBL] [Abstract] [Full Text] [Related]
7. Deep Targeted Sequencing and Its Potential Implication for cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.
Yu P; Wang Y; Yu Y; Wang A; Huang L; Zhang Y; Liu W; Wu H; Yao M; Du YA; Cheng X
Oncologist; 2021 May; 26(5):e756-e768. PubMed ID: 33511732
[TBL] [Abstract] [Full Text] [Related]
8. Establishment and characterization of NCC-mfs2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma.
Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2021 Jan; 34(1):246-253. PubMed ID: 32870449
[TBL] [Abstract] [Full Text] [Related]
9. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in pancreatic cancer.
Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
[TBL] [Abstract] [Full Text] [Related]
10. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in pancreatic cancer.
Totiger TM; Srinivasan S; Jala VR; Lamichhane P; Dosch AR; Gaidarski AA; Joshi C; Rangappa S; Castellanos J; Vemula PK; Chen X; Kwon D; Kashikar N; VanSaun M; Merchant NB; Nagathihalli NS
Mol Cancer Ther; 2019 Feb; 18(2):301-311. PubMed ID: 30404927
[TBL] [Abstract] [Full Text] [Related]
11. Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer.
Takahashi R; Hirata Y; Sakitani K; Nakata W; Kinoshita H; Hayakawa Y; Nakagawa H; Sakamoto K; Hikiba Y; Ijichi H; Moses HL; Maeda S; Koike K
Cancer Sci; 2013 Mar; 104(3):337-44. PubMed ID: 23237571
[TBL] [Abstract] [Full Text] [Related]
